Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries

Table 2 Simulated results for screening strategies to prevent CRC*

Variable	Screening Strategy
	No Screening	DNA₃	DNA₅	DNA₁₀	FOBT₁	SIGM₅	COLO₁₀
Total cases of CRC, n	2,917	2,435	2,654	2,710	2,129	2,253	1,780
CRC deaths, n	1,729	1,345	1,467	1,574	1,059	1,328	1,077
Perforation deaths, n	0	3	2	1	5	3	12
Reduction in CRC incidence, %	0	17	9	7	27	23	39
Reduction in CRC mortality, %	0	22	15	9	39	23	39
Life expectancy, year	15.7337	15.7476	15.7434	15.7400	15.7584	15.7477	15.7590
Total costs, thousand $	22,022	35,637	31,077	26,856	19,824	24,909	21,843
Incremental life-year saved, year	0	1,390	970	626	2,464	1,383	2,530
Incremental cost, thousand $	0	13,615	9,054	4,834	-2,198	2,887	-180
Incremental cost ($)/life-years saved compared with no screening	0	9,794	9,335	7,717	Dominant‡	2,087	Dominant‡
Incremental cost ($)/life-years saved:
DNA₃vs. other screening strategies	--	--	--	--	Dominant†	Dominant†	Dominant†
DNA₅ vs. other screening strategies	--	--	--	--	Dominant†	Dominant†	Dominant†
DNA₁₀ vs. other screening strategies	--	--	--	--	Dominant†	Dominant†	Dominant†

Abbreviations: CRC, colorectal cancer; DNA₃, stool DNA testing every 3 years; DNA₅, stool DNA testing every 5 years; DNA₁₀, stool DNA testing every 10 years; FOBT₁, fecal occult blood testing every two year; SIGM₅, sigmoidoscopy every 5 years; COLO₁₀, colonoscopy every 10 years.
* Values obtain from a cohort of 100,000 persons 50 years of age who were followed for 25 years.
† The other screening strategy is more effective and less costly than stool DNA testing strategy.
‡ The screening is more effective and less costly than No Screening.

ISSN: 1471-2407